Literature DB >> 15349047

Objective measurement of allergic reactions in the eye.

Mitchell H Friedlaender1.   

Abstract

PURPOSE OF REVIEW: Conjunctival allergen challenge has become a useful model of human ocular allergy and an accepted method for studying the effects of topical antiinflammatory medications. Conjunctival allergen challenge reactions are typically evaluated in a subjective fashion. Erythema and edema are graded by observation, using a 0 to 4 scale. Itching is graded on a 0 to 4 scale by questioning the subject. We have reviewed the recent literature on conjunctival allergen challenge, including recently developed methods aimed at objective assessment of ocular allergic reactions, such as the erythema, edema, sensation, or EES, method. RECENT
FINDINGS: Conjunctival erythema can be measured objectively using a spectroradiometer, or colorimeter, a device which measures the chromaticity of reflected light, and provides the x, or u', and y, or v', coordinates of any color. Edema of the eyelids and conjunctiva can be measured using a fractional millimeter reticule in the eyepiece of a slit lamp microscope. Ocular surface sensation can be evaluated using the aesthesiometer of Cochet and Bonnet, or by using a 'sensation index', a measurement that takes into account the intensity and duration of itching.
SUMMARY: CAC reactions can be measured objectively using the erythema, edema, sensation method, as well as subjectively by observation and questioning.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15349047     DOI: 10.1097/00130832-200410000-00019

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  2 in total

1.  Potential bias in ophthalmic pharmaceutical clinical trials.

Authors:  Paul Varner
Journal:  Clin Ophthalmol       Date:  2008-06

2.  Comparison of different smartphone cameras to evaluate conjunctival hyperaemia in normal subjects.

Authors:  Carles Otero; Nery García-Porta; Juan Tabernero; Shahina Pardhan
Journal:  Sci Rep       Date:  2019-02-04       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.